Dr. Reddy’s shines on launching Hervycta in India

26 Jul 2018 Evaluate

Dr. Reddy's Laboratories is currently trading at Rs. 2160.00, up by 71.00 points or 3.40% from its previous closing of Rs. 2089.00 on the BSE.

The scrip opened at Rs. 2086.00 and has touched a high and low of Rs. 2189.95 and Rs. 2075.60 respectively. So far 102940 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2725.00 on 27-Jul-2017 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2,189.95 and Rs. 2017.20 respectively. The current market cap of the company is Rs. 34818.26 crore.

The promoters holding in the company stood at 26.79%, while Institutions and Non-Institutions held 44.27% and 14.60% respectively.

Dr. Reddy’s Laboratories has launched Hervycta (Trastuzumab), a biosimilar of Roche's Herceptin in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer).

Dr. Reddy’s Hervycta is available in strengths of 150mg and 440mg multiple dose vials. Dr. Reddy’s currently has four biosimilar products commercialized in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.

Herceptin (marketed as Herclon in India) and its biosimilars had India sales of around Rs 290 crore MAT for the most recent twelve months ending in December 2017 according to Ipsos.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

5913.95 -2.85 (-0.05%)
13-May-2024 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1530.00
Dr. Reddys Lab 5913.95
Cipla 1421.00
Zydus Lifesciences 993.40
Lupin 1684.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.